A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs

Abstract

Solute carriers (SLCs) are the largest family of transmembrane transporters in humans and are major determinants of cellular metabolism. Several SLCs have been shown to be required for the uptake of chemical compounds into cellular systems, but systematic surveys of transporter–drug relationships in human cells are currently lacking. We performed a series of genetic screens in a haploid human cell line against 60 cytotoxic compounds representative of the chemical space populated by approved drugs. By using an SLC-focused CRISPR–Cas9 library, we identified transporters whose absence induced resistance to the drugs tested. This included dependencies involving the transporters SLC11A2/SLC16A1 for artemisinin derivatives and SLC35A2/SLC38A5 for cisplatin. The functional dependence on SLCs observed for a significant proportion of the screened compounds suggests a widespread role for SLCs in the uptake and cellular activity of cytotoxic drugs and provides an experimentally validated set of SLC–drug associations for a number of clinically relevant compounds.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Experimental setup and overview of the screened compound set.
Fig. 2: Identification of enriched SLCs upon compound treatment.
Fig. 3: Validation of a set of SLC/compound associations by multicolor competition assay (MCA).
Fig. 4: Characterization of selected SLC/drug associations.
Fig. 5: Chemoinformatic analysis of the compound subsets employed in this study.

Data availability

The data and code that support the findings of this study are available on request from the corresponding author. Data used to generate Figs. 2c and 3b and Supplementary Fig. 3b are available in Supplementary Datasets 1 and 2.

References

  1. 1.

    Gonzalez, F. J., Coughtrie, M. & Tukey, R. H. in Goodman & Gilman’s: The Pharmacological Basis of Therapeutics (eds Brunton, L. L., Chabner, B. A. & Knollmann, B. C.) Ch. 6 (McGraw-Hill Education, 2015).

  2. 2.

    Nigam, S. K. What do drug transporters really do? Nat. Rev. Drug Discov. 14, 29–44 (2014).

  3. 3.

    César-Razquin, A. et al. A call for systematic research on solute carriers. Cell 162, 478–487 (2015).

  4. 4.

    Fletcher, J. I., Haber, M., Henderson, M. J. & Norris, M. D. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 10, 147–156 (2010).

  5. 5.

    Hediger, M. A., Clémençon, B., Burrier, R. E. & Bruford, E. A. The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol. Aspects Med. 34, 95–107 (2013).

  6. 6.

    Motohashi, H. & Inui, K. Multidrug and toxin extrusion family SLC47: physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. Mol. Aspects Med. 34, 661–668 (2013).

  7. 7.

    Estudante, M., Soveral, G., Morais, J. G. & Benet, L. Z. Insights into solute carriers: physiological functions and implications in disease and pharmacokinetics. MedChemComm 7, 1462–1478 (2016).

  8. 8.

    Geier, E. G. et al. Profiling solute carrier transporters in the human blood–brain barrier. Clin. Pharmacol. Ther. 94, 636–639 (2013).

  9. 9.

    Giacomini, K. M. et al. International transporter consortium commentary on clinically important transporter polymorphisms. Clin. Pharmacol. Ther. 94, 23–26 (2013).

  10. 10.

    US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Clinical Drug Interaction Studies—Study Design, Data Analysis, and Clinical Implications (2017).

  11. 11.

    Matsson, P. et al. Quantifying the impact of transporters on cellular drug permeability. Trends Pharmacol. Sci. 36, 255–262 (2015).

  12. 12.

    Dobson, P. D. & Kell, D. B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat. Rev. Drug Discov. 7, 205–220 (2008).

  13. 13.

    Sugano, K. et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat. Rev. Drug Discov. 9, 597–614 (2010).

  14. 14.

    Young, J. D., Yao, S. Y. M., Baldwin, J. M., Cass, C. E. & Baldwin, S. A. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol. Aspects Med. 34, 529–547 (2013).

  15. 15.

    Icard, P. et al. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist. Updat. 38, 1–11 (2018).

  16. 16.

    Reczek, C. R. et al. A CRISPR screen identifies a pathway required for paraquat-induced cell death. Nat. Chem. Biol. 13, 1274–1279 (2017).

  17. 17.

    Winter, G. E. et al. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nat. Chem. Biol. 10, 768–773 (2014).

  18. 18.

    Birsoy, K. et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat. Genet. 45, 104–108 (2012).

  19. 19.

    Reiling, J. H. et al. A haploid genetic screen identifies the major facilitator domain containing 2A (MFSD2A) transporter as a key mediator in the response to tunicamycin. Proc. Natl Acad. Sci. USA 108, 11756–11765 (2011).

  20. 20.

    Blomen, V. A. et al. Gene essentiality and synthetic lethality in haploid human cells. Science 350, 1092–1096 (2015).

  21. 21.

    Klein, M.-C. et al. AXER is an ATP/ADP exchanger in the membrane of the endoplasmic reticulum. Nat. Commun. 9, 3489 (2018).

  22. 22.

    Robinson, A. J., Kunji, E. R. S. & Gross, A. Mitochondrial carrier homolog 2 (MTCH2): the recruitment and evolution of a mitochondrial carrier protein to a critical player in apoptosis. Exp. Cell Res. 318, 1316–1323 (2012).

  23. 23.

    O’Hagan, S., Wright Muelas, M., Day, P. J., Lundberg, E. & Kell, D. B. GeneGini: assessment via the Gini coefficient of reference ‘housekeeping’ genes and diverse human transporter expression profiles. Cell Syst. 6, 230–244 (2018).

  24. 24.

    César-Razquin, A. et al. In silico prioritization of transporter–drug relationships from drug sensitivity screens. Front. Pharmacol. 9, 1011 (2018).

  25. 25.

    Licciardello, M. P. et al. A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. Nat. Chem. Biol. 13, 771–778 (2017).

  26. 26.

    Zhao, R., Diop-Bove, N., Visentin, M. & Goldman, I. D. Mechanisms of membrane transport of folates into cells and across epithelia. Annu. Rev. Nutr. 31, 177–201 (2011).

  27. 27.

    Sirotnak, F. M., DeGraw, J. I., Moccio, D. M., Samuels, L. L. & Goutas, L. J. New folate analogs of the 10-deaza-aminopterin series Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother. Pharmacol. 12, 18–25 (1984).

  28. 28.

    Waalkes, T. P. & Makulu, D. R. Pharmacologic aspects of pentamidine. Natl Cancer Inst. Monogr. 43, 171–177 (1976).

  29. 29.

    Grottker, J., Rosenberger, A., Burckhardt, G. & Hagos, Y. Interaction of human multidrug and toxin extrusion 1 (MATE1) transporter with antineoplastic agents. Drug Metabol. Drug Interact. 26, 181–189 (2011).

  30. 30.

    Yang, N.-D. et al. Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. J. Biol. Chem. 289, 33425–33441 (2014).

  31. 31.

    Cui, L. & Su, X. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev. Anti Infect. Ther. 7, 999–1013 (2009).

  32. 32.

    Montalbetti, N., Simonin, A., Kovacs, G. & Hediger, M. A. Mammalian iron transporters: families SLC11 and SLC40. Mol. Aspects Med. 34, 270–287 (2013).

  33. 33.

    Kell, D. B. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med. Genomics 2, 2 (2009).

  34. 34.

    Pérez-Escuredo, J. et al. Monocarboxylate transporters in the brain and in cancer. Biochim. Biophys. Acta Mol. Cell Res. 1863, 2481–2497 (2016).

  35. 35.

    Song, Z. Roles of the nucleotide sugar transporters (SLC35 family) in health and disease. Mol. Aspects Med. 34, 590–600 (2013).

  36. 36.

    Schiöth, H. B., Roshanbin, S., Hägglund, M. G. A. & Fredriksson, R. Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects. Mol. Aspects Med. 34, 571–585 (2013).

  37. 37.

    Våtsveen, T. K. et al. Artesunate shows potent anti-tumor activity in B-cell lymphoma. J. Hematol. Oncol. 11, 23 (2018).

  38. 38.

    Wang, N., Zeng, G.-Z., Yin, J.-L. & Bian, Z.-X. Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt’s lymphoma. Biochem. Biophys. Res. Commun. 519, 533–539 (2019).

  39. 39.

    St Germain, C. et al. Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3. Neoplasia 12, 527–538 (2010).

  40. 40.

    Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074–D1082 (2017).

  41. 41.

    Yu, Z. et al. Identification of a transporter complex responsible for the cytosolic entry of nitrogen-containing bisphosphonates. eLife 7, e36620 (2018).

  42. 42.

    Yee, S. W. et al. SLC19A1 pharmacogenomics summary. Pharmacogenet. Genomics 20, 708–715 (2010).

  43. 43.

    Pastor-Anglada, M. & Pérez-Torras, S. Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. Front. Pharmacol. 6, 13 (2015).

  44. 44.

    Lai, H. & Singh, N. P. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett. 91, 41–46 (1995).

  45. 45.

    Duan, G. et al. Increased glutamine consumption in cisplatin-resistant cells has a negative impact on cell growth. Sci. Rep. 8, 4067 (2018).

  46. 46.

    Guidi, N. & Longo, V. D. Periodic fasting starves cisplatin‐resistant cancers to death. EMBO J. 37, e99815 (2018).

  47. 47.

    Yamada, D. et al. Inhibition of the glutamine transporter SNAT1 confers neuroprotection in mice by modulating the mTOR-autophagy system. Commun. Biol. 2, 346 (2019).

  48. 48.

    Farge, T. et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 7, 716–735 (2017).

  49. 49.

    Bhattacharya, B., Mohd Omar, M. F. & Soong, R. The Warburg effect and drug resistance: the Warburg effect and drug resistance. Br. J. Pharmacol. 173, 970–979 (2016).

  50. 50.

    Lanthaler, K. et al. Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeast. BMC Biol. 9, 70 (2011).

  51. 51.

    Doench, J. G. et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat. Biotechnol. 32, 1262–1267 (2014).

  52. 52.

    Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).

  53. 53.

    Heigwer, F., Kerr, G. & Boutros, M. E-CRISP: fast CRISPR target site identification. Nat. Methods 11, 122–123 (2014).

  54. 54.

    Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).

  55. 55.

    Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583–588 (2014).

  56. 56.

    Montague, T. G., Cruz, J. M., Gagnon, J. A., Church, G. M. & Valen, E. CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic Acids Res. 42, W401–W407 (2014).

  57. 57.

    Bigenzahn, J. W. et al. LZTR1 is a regulator of RAS ubiquitination and signaling. Science 362, 1171–1177 (2018).

  58. 58.

    Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).

  59. 59.

    Moskovskich, A. et al. The transporters SLC35A1 and SLC30A1 play opposite roles in cell survival upon VSV virus infection. Sci. Rep. 9, 10471 (2019).

Download references

Acknowledgements

We thank all members of the Superti-Furga laboratory for discussions and feedback. We are also grateful to the Biomedical Sequencing facility for advice on Illumina sequencing and to the Flow Cytometry Core Facility of the Vienna Medical University for help with FACS sorting. We also thank B. Vilagos for graphical input and advice and S. Sdelci for scientific discussions and insights. We acknowledge support by the Austrian Academy of Sciences, the European Research Council (ERC AdG 695214 GameofGates, to E.G. and G.F.), the Austrian Science Fund (FWF I2192-B22 ERASE, to A.C.-R.; FWF P29250-B30 VITRA, to E.G., J.K. and G.F.) and also a Marie Sklodowska-Curie fellowship to E.G. (MSCA-IF-2014-661491). Research in the Kubicek laboratory is supported by the Austrian Federal Ministry for Digital and Economic Affairs and the National Foundation for Research, Technology and Development, the Austrian Science Fund (FWF) F4701 and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (ERC-CoG-772437). The Pharmacoinformatics Research Group (Ecker lab) acknowledges funding provided by the Austrian Science Fund FWF AW012321 MolTag.

Author information

E.G., G.S.-F. conceived and designed the study. E.G., K.P., S.L., J.K., B.G., K.K., G.F., A.I.-P., F.K., A.K. and C.-H.L. performed experiments and analyzed data. A.C.-R. analyzed screening and validation data. V.S. analyzed the transcriptomics data. J.H., S. Kickinger and G.F.E. performed the chemoinformatic analysis. R.K.K. contributed to library design. S. Kubicek, G.F.E. and G.S.-F. provided supervision.

Correspondence to Giulio Superti-Furga.

Ethics declarations

Competing interests

C.-H.L. is an employee of AstraZeneca Limited (UK). The other authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Supplementary Tables 1–5 and Figs. 1–6.

Reporting Summary

Supplementary Dataset 1

P and FDR values used to generate Fig. 2c.

Supplementary Dataset 2

Ratios and P values used to generate Fig. 3b and Supplementary Fig. 3b.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Girardi, E., César-Razquin, A., Lindinger, S. et al. A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs. Nat Chem Biol 16, 469–478 (2020). https://doi.org/10.1038/s41589-020-0483-3

Download citation

Further reading